KALA BIO, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited; amounts below are in millions of dollars unless noted.
Business context
KALA BIO is a clinical-stage biopharmaceutical company focused on rare and severe eye diseases. Its lead candidate, KPI-012, is in a Phase 2b trial for persistent corneal epithelial defects (PCED). The company sold its commercial business, including EYSUVIS and INVELTYS, to Alcon in July 2022 and has no revenue-generating commercial products. It reported 2,693,116 common shares outstanding as of November 10, 2023.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Product revenue | $0 | $0.420 | $0 | $3.892 |
| Operating loss | $8.762 | $14.569 | $30.044 | $71.455 |
| Net loss (income) | $8.704 loss | $29.073 income | $33.572 loss | $31.979 loss |
| Research and development expense | $5.554 | $5.391 | $13.868 | $14.330 |
| Selling, general and administrative expense | $4.952 | $9.549 | $15.944 | $59.204 |
| Cash used in operating activities | Not presented by quarter | $20.231 | $65.173 |
- Margins: Gross margin is not meaningful for 2023 because there were no product revenues or cost of product revenues.
- Cash and liquidity: Cash and cash equivalents were $56.063 at September 30, 2023, down from $70.495 at December 31, 2022. Current assets were $57.902 and current liabilities $10.301, approximately 5.6 times current-asset coverage.
- Debt: Debt carrying value was $33.878; principal outstanding was $33.957. The loan bears a floating rate with an 8.00% minimum. Scheduled amortization begins January 2025 under the stated terms.
- Equity and funding: Stockholders’ equity was $11.223, compared with $18.974 at year-end 2022. The company raised $17.966 net from at-the-market common-stock sales during the first nine months.
Material changes versus comparable periods
- Revenue ceased following the 2022 Alcon sale. The prior-year nine-month period included $3.892 in product revenue.
- SG&A fell substantially, mainly due to the commercial-business sale and workforce reduction completed in 2022. Nine-month R&D was slightly lower overall, although KPI-012 development costs increased to $5.838 from $4.698.
- Operating cash use improved to $20.231 from $65.173, largely reflecting lower operating costs and working-capital changes. The 2022 investing cash flow included $62.908 of net proceeds from the Alcon sale; 2023 did not.
- Q3 2022 net income reflected a $46.995 gain on the Alcon sale. Excluding that unusual item, the comparison is between operating losses in both quarters. The 2023 nine-month net loss also included a $4.253 net other expense, including write-offs and adjustments related to the former commercial business.
Outlook, commentary and risks
- Management targeted topline safety and efficacy data from the CHASE Phase 2b trial in the second half of 2024. The trial’s final cohort is a randomized, vehicle-controlled study of approximately 90 patients; the primary endpoint is complete healing of PCED.
- The company recognized $2.970 of CIRM grant income in Q3 and the first nine months. The $15.0 award included an initial $5.9 disbursement; the remaining funding is milestone- and co-funding-dependent. Management anticipated the cash balance plus remaining CIRM funding would support operations into Q2 2025, but said existing resources would not fund completion of KPI-012 clinical development.
- Management expects continued operating losses, no product revenue for the foreseeable future, and increased R&D spending as KPI-012 advances. It stated that it may need additional capital; financing may dilute shareholders or may not be available on acceptable terms.
- Key risks include clinical-trial outcomes and enrollment, regulatory approval, reliance on third-party manufacturing and trial operators, uncertain Alcon sales milestones (none received to date; up to $325.0 in total), and CIRM milestone compliance. Oxford debt covenants include Nasdaq-listing requirements; a default could accelerate repayment. The company reported no material legal proceedings.
Investor facts to verify
- Whether CHASE enrollment and execution remain on schedule and whether second-half 2024 topline data timing is maintained.
- Cash burn, actual timing and availability of remaining CIRM funds, and the resulting runway; the runway estimate depends on assumptions and milestone funding.
- Debt terms, floating-rate exposure, future repayment requirements, and compliance with Oxford covenants and Nasdaq listing standards.
- Any future Alcon milestone receipts and the extent of additional equity or other financing, including potential dilution.
- Reconciliation of unusual 2023 write-offs and contingent-consideration fair-value movements, which affected reported expenses and results.